Clinical Trials Browser

Phase 2 × Completed × anlotinib × Clear all

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Phase 2 Completed

Nasopharyngeal Carcinoma, Recurrence

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Phase 2 Completed

NSCLC

NCT05493995 2024-05-09

PAAG

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT04271813 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03906058 2023-10-25

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

Lung Neoplasms

NCT06015035 2023-08-29

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase 2 Completed

Neoplasm Metastasis

NCT03743129 2023-06-12

ALTER-L029

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05130515 2023-01-31

CC-ANNIE

Phase 2 Completed

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT03736837 2021-03-15

ALTER-L004

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

Phase 2 Completed

Advanced Malignancy

NCT01878448 2019-05-22

ALTN/STS

Phase 2 Completed

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

Phase 2 Completed

Neoplasms

NCT03059797 2019-05-16

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Phase 2 Completed

Small Cell Lung Carcinoma

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms